KR830010073A - 1,4-디하이드로피리딘 유도체의 제조방법 - Google Patents

1,4-디하이드로피리딘 유도체의 제조방법 Download PDF

Info

Publication number
KR830010073A
KR830010073A KR1019820001696A KR820001696A KR830010073A KR 830010073 A KR830010073 A KR 830010073A KR 1019820001696 A KR1019820001696 A KR 1019820001696A KR 820001696 A KR820001696 A KR 820001696A KR 830010073 A KR830010073 A KR 830010073A
Authority
KR
South Korea
Prior art keywords
group
general formula
same
alkyl
compound represented
Prior art date
Application number
KR1019820001696A
Other languages
English (en)
Other versions
KR900004923B1 (ko
Inventor
데쓰지 미야노
구니오 스즈끼
노부오 하라다
아끼라 아사이
Original Assignee
이와다레 고오이찌
반유세이야꾸 가부시기 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이와다레 고오이찌, 반유세이야꾸 가부시기 가이샤 filed Critical 이와다레 고오이찌
Publication of KR830010073A publication Critical patent/KR830010073A/ko
Application granted granted Critical
Publication of KR900004923B1 publication Critical patent/KR900004923B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

1,4-디하이드로피리딘 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. (가) 일반식(Ⅱ)
    (식중,R1 a은 디알콕시알킬기를, R2은 알콕시알킬기, 알케닐옥시알킬기, 아릴옥시알키기 또는 아랄킬옥시알킬기를, R5은 o-, m- 또는 p-니트로기를 각각 뜻한다)로 나타내는 화합물로 일반식(Ⅲ)
    [식중, R3은 알킬기, 할로알킬기, 알콕시알킬기, 알케닐옥시알킬기, 아릴옥시알킬기, 아랄킬옥시알킬기또는 N,N-디치환아미노알킬기(치환기로서는 동일 또는 다른 알킬기, 아랄킬기 또는 아릴기를 뜻한다.)을, R4 a은 알킬기 또는 디알콕시알킬기를 각각 뜻한다.]로 나타내는 아민 화합물을 반응시키든지 또는 일반식(Ⅳ)
    (식중, R3, R4 a및 R5은 전기와 같은 뜻임)로 나타내는 화합물에 일반식(Ⅴ)
    (식중, R1 a및 R2은 전기와 같은 뜻임)로 나타내는 아민화합물을 반응시켜서 일반식(Ⅵ)
    (식중, R1 a,R2,R3,R4 a및 R5은 전기와 같은 뜻임)로 나타내는 화합물을 제조하는 방법,
    (나) 일반식(Ⅵ)
    (식중, R1 a,R2,R3,R4 a및 R5은 전기와 같은 뜻임)로 나타내는 화합물을 가수분해하여 일반식(Ⅶ)
    (식중, R1 b은 포밀기 또는 포밀알킬기를, R4 b은 알킬기, 포밀기 또는 포밀알킬기를, R2,R3및 R5은 각각 전기와 같은 뜻임)로 나타내는 화합물을 제조하는 방법,
    (다) 일반식(Ⅶ)
    (식중, R1 b,R2,R3,R4 b및 R5은 전기와 같은 뜻임)로 나타내는 화합물로 환원하여 일반식(Ⅷ)
    (식중, R1 c은 히드록시알킬기를, R4 c은 알킬기 또는 히드록시알킬기를, R2,R3및 R5은 각각 전기와 같은 뜻임)로 나타내는 화합물을 제조하는 방법 및
    (라) 일반식(Ⅸ)
    (식중, R1은 디알콕시알킬기, 포밀기, 포밀알킬기 또는 히드록시알킬기를, R3 a은 할로알킬기를, R4 d은 알킬기를, R2및 R5은 각각 전기와 같은 뜻임)로 나타내는 화합물에 일반식(Ⅹ)
    (식중, R′과 R″은 동일 또는 다른 알킬기, 아랄킬기 또는 아릴기를 뜻함)로 나타내는 아민화합물을 반응시켜서 일반식(XI)
    (식중, R3 b은 N,N-디치환아미노알킬기(치환기로서는 동일 또는 다른 알킬기, 아랄킬기 또는 아릴기를 뜻함)을, R1,R2,R4 d및 R5은 각각 전기와 같은 뜻임)로 나타내는 화합물을 제조하는 방법으로써 되는 일반식(Ⅰ)
    (식중, R1,R2,R3및 R5은 전기와 같은 뜻이며, R4은 알킬기, 디알콕시알킬기, 포밀기, 포밀알킬기 또는 히드록시알킬기를 뜻함)로 나타내는 1,4-디히드로피리딘 유도체의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR8201696A 1981-04-18 1982-04-17 1,4-디히드로피리딘 유도체의 제조방법 KR900004923B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP56057855A JPS57175164A (en) 1981-04-18 1981-04-18 1,4-dihydropyridine derivative and its preparation
JP57855/1981 1981-04-18
JP?56-57855 1981-04-18

Publications (2)

Publication Number Publication Date
KR830010073A true KR830010073A (ko) 1983-12-26
KR900004923B1 KR900004923B1 (ko) 1990-07-12

Family

ID=13067598

Family Applications (1)

Application Number Title Priority Date Filing Date
KR8201696A KR900004923B1 (ko) 1981-04-18 1982-04-17 1,4-디히드로피리딘 유도체의 제조방법

Country Status (6)

Country Link
EP (1) EP0063359B1 (ko)
JP (1) JPS57175164A (ko)
KR (1) KR900004923B1 (ko)
CA (1) CA1176255A (ko)
DE (1) DE3267874D1 (ko)
HU (1) HU186494B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125803A3 (en) * 1983-04-27 1987-01-21 FISONS plc Pharmaceutically active dihydropyridines
US4686217A (en) * 1983-04-27 1987-08-11 Fisons Plc Calcium antagonist 2-fluoroalkyl-1,4-dihydropyridines
JPS60120861A (ja) * 1983-12-02 1985-06-28 Otsuka Pharmaceut Co Ltd ジヒドロピリジン誘導体
JPS60156671A (ja) * 1984-01-25 1985-08-16 Yamanouchi Pharmaceut Co Ltd ジヒドロピリジン誘導体およびその製造法
US4672068A (en) * 1984-05-04 1987-06-09 Fujirebio Kabushiki Kaisha Antihypertensive 1,4-dihydropyridines having a conjugated ester
US6265127B1 (en) * 1999-12-15 2001-07-24 Eastman Kodak Company 1, 4-dihydrophyridine charge control agents for electrostatographic toners and developers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5084577A (ko) * 1973-11-29 1975-07-08
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof
GB1591089A (en) * 1976-12-17 1981-06-10 Fujisawa Pharmaceutical Co 1,4-dihydropyridine derivatives and process for preparation thereof
DE2650013C3 (de) * 1976-10-30 1981-04-02 Bayer Ag, 5090 Leverkusen 1.4-Dihydro-2.6-dimethyl-4-(3-nitrophenyl)-3.5-pyridindicarbonsäureisopropyl-(2-propoxy-äthyl)-ester, Verfahren zu seiner Herstellung sowie ihn enthaltende Arzneimittel
US4307103A (en) * 1978-09-08 1981-12-22 Fujisawa Pharmaceutical Co., Ltd. Dihydropyridine derivative, processes for preparation thereof and pharmaceutical composition comprising the same
CA1117117A (en) * 1978-10-10 1982-01-26 Fujisawa Pharmaceutical Co., Ltd. 2-methyl-dihydropyridine compound, processes for preparation thereof and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
EP0063359A1 (en) 1982-10-27
HU186494B (en) 1985-08-28
DE3267874D1 (en) 1986-01-23
JPS57175164A (en) 1982-10-28
KR900004923B1 (ko) 1990-07-12
CA1176255A (en) 1984-10-16
JPH036140B2 (ko) 1991-01-29
EP0063359B1 (en) 1985-12-11

Similar Documents

Publication Publication Date Title
KR850005826A (ko) 1,4-디히드로-2,6-디메틸피리딘-3,5-디카르복실산의 비대칭 디에스테르의 제조방법
KR830007607A (ko) 카보스티릴 화합물의 제조방법
KR830010104A (ko) 아릴페닐 에테르 유도체의 제조방법
ATE89559T1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung.
KR830007685A (ko) 세팔로스포린 유도체의 제조방법
KR880002823A (ko) 약제학적 화합물
KR840008001A (ko) 티아졸리딘 유도체의 제조방법
KR860002496A (ko) 카보닐 화합물의 제조방법
KR850002964A (ko) 심장병 치료제의 제조방법
KR870003100A (ko) 벤즈이미다졸 유도체
KR850004492A (ko) 옥시캄의 엔올 에테르 유도체의 제조방법
KR840000534A (ko) 디히드로피리딘 화합물류의 제조방법
KR830010073A (ko) 1,4-디하이드로피리딘 유도체의 제조방법
KR890011829A (ko) 디우레아 유도체 및 이의 제조방법
KR840006482A (ko) 디히드로피라졸로 [3,4-b]피리딘 유도체의 제조방법
KR830010110A (ko) 티에닐옥시프로판올 아민의 치환된 트립트아민 유도체의 제조방법
KR860002450A (ko) 아미노-알콜유도체의 제조방법
KR840000521A (ko) 3-메틸플라본-8-카르복실산 에스테르류의 제조방법
KR840005723A (ko) 티아졸유도체의 제조방법
KR860006453A (ko) 트리아지닐을 함유하는 스틸벤 유도체의 제조방법
KR850007256A (ko) 트리사이클릭 이미다졸 유도체의 제조방법
KR860004051A (ko) 치환된 페닐피페라진 유도체의 제조방법
KR840001154A (ko) 1,2-디티올-3-일리덴 암모늄 유도체의 제조방법
KR860003224A (ko) N-벤조일 페닐 우레아의 제조방법
KR830006293A (ko) 신규 폴리아자 헤테로고리 화합물의 제조방법